Literature DB >> 1782985

Kinetics of cholinesterase inhibition by eptastigmine in man.

L K Unni, V Hutt, B P Imbimbo, R E Becker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1782985     DOI： 10.1007/BF00280116

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  11 in total

1.  Extraction of physostigmine from biologic fluids and analysis by liquid chromatography with electrochemical detection.

Authors:  G D Lawrence; N Yatim
Journal:  J Pharmacol Methods       Date:  1990-09

2.  A rapid, simple radiometric assay for cholinesterase, suitable for multiple determinations.

Authors:  C D Johnson; R L Russell
Journal:  Anal Biochem       Date:  1975-03       Impact factor: 3.365

3.  Anticholinesterase activity of a new carbamate, heptylphysostigmine, in view of its use in patients with Alzheimer-type dementia.

Authors:  M Brufani; M Marta; M Pomponi
Journal:  Eur J Biochem       Date:  1986-05-15

4.  Diagnosing dementia and its treatable causes.

Authors:  K Steel; R G Feldman
Journal:  Geriatrics       Date:  1979-03

5.  The effect of heptyl-physostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat.

Authors:  P De Sarno; M Pomponi; E Giacobini; X C Tang; E Williams
Journal:  Neurochem Res       Date:  1989-10       Impact factor: 3.996

6.  Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain.

Authors:  P J Whitehouse; D L Price; R G Struble; A W Clark; J T Coyle; M R Delon
Journal:  Science       Date:  1982-03-05       Impact factor: 47.728

7.  Physostigmine effects in Alzheimer's disease: relationship to dementia severity.

Authors:  A S Schwartz; E V Kohlstaedt
Journal:  Life Sci       Date:  1986-03-17       Impact factor: 5.037

8.  New analogs of physostigmine: alternative drugs for Alzheimer's disease?

Authors:  M Marta; C Castellano; A Oliverio; F Pavone; P G Pagella; M Brufani; M Pomponi
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

9.  Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine.

Authors:  K L Davis; R C Mohs
Journal:  Am J Psychiatry       Date:  1982-11       Impact factor: 18.112

10.  Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type.

Authors:  W K Summers; L V Majovski; G M Marsh; K Tachiki; A Kling
Journal:  N Engl J Med       Date:  1986-11-13       Impact factor: 91.245
View more
  7 in total

1.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

2.  Some blood biochemistry parameters during the cholinergic treatment of Alzheimer's disease.

Authors:  F I Braginskaya; M Zorina; N P Pal'mina; V D Gaintseva; E B Burlakova; N D Selezneva; I V Kolykhalov; S I Gavrilova
Journal:  Neurosci Behav Physiol       Date:  2001 Jul-Aug

Review 3.  Cholinesterase inhibitors for the treatment of Alzheimer's disease in the elderly.

Authors:  C M VanDenBerg; Y Kazmi; M W Jann
Journal:  Drugs Aging       Date:  2000-02       Impact factor: 3.923

4.  Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects.

Authors:  A Auteri; A Mosca; N Lattuada; M Luzzana; L Zecca; D Radice; B P Imbimbo
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 5.  Clinical pharmacokinetics of drugs for Alzheimer's disease.

Authors:  L Parnetti
Journal:  Clin Pharmacokinet       Date:  1995-08       Impact factor: 6.447

Review 6.  [Relations between specific neurochemical systems and memory: problems posed by dementia of the Alzheimer type].

Authors:  I Lussier; E Stip
Journal:  J Psychiatry Neurosci       Date:  1995-01       Impact factor: 6.186

Review 7.  The PI3K/AKT/mTOR signaling pathway inhibitors enhance radiosensitivity in cancer cell lines.

Authors:  Alireza Mardanshahi; Nasrin Abbasi Gharibkandi; Samaneh Vaseghi; Seyed Mohammad Abedi; Sajjad Molavipordanjani
Journal:  Mol Biol Rep       Date:  2021-08-06       Impact factor: 2.316
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.